Stockscreener 앱 받기
18.12
0.82%
-0.15
시간 외 거래:
18.11
-0.01
-0.06%
전일 마감가:
$18.27
열려 있는:
$18.28
하루 거래량:
18,519
Relative Volume:
0.33
시가총액:
$823.68M
수익:
-
순이익/손실:
$-75.28M
주가수익비율:
-9.0795
EPS:
-1.9957
순현금흐름:
$-57.45M
1주 성능:
+5.59%
1개월 성능:
-7.41%
6개월 성능:
+9.35%
1년 성능:
+53.82%
1일 변동 폭
$17.76
$18.28
1주일 범위
$17.35
$18.55
52주 변동 폭
$10.79
$23.08
Oculis Holding Ag Stock (OCS) Company Profile
OCS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OCS
Oculis Holding Ag
|
18.12 | 823.68M | 0 | -75.28M | -57.45M | -1.9957 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Oculis Holding Ag Stock (OCS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-12-05 | 개시 | Chardan Capital Markets | Buy |
| 2023-10-05 | 개시 | Stifel | Buy |
| 2023-06-14 | 개시 | BofA Securities | Buy |
| 2023-06-12 | 개시 | H.C. Wainwright | Buy |
| 2023-06-08 | 개시 | Robert W. Baird | Outperform |
| 2023-05-10 | 개시 | Pareto | Buy |
| 2023-04-28 | 개시 | Wedbush | Outperform |
모두보기
Oculis Holding Ag 주식(OCS)의 최신 뉴스
(OCS) Trading Advice - news.stocktradersdaily.com
HC Wainwright Increases Oculis (NASDAQ:OCS) Price Target to $32.00 - Defense World
Chardan Capital Reaffirms Buy Rating for Oculis (NASDAQ:OCS) - Defense World
Oculis (NASDAQ:OCS) Shares Gap Up Following Analyst Upgrade - Defense World
Oculis and EURETINA Announce the 2025 Ramin Tadayoni Award - The Manila Times
Oculis and EURETINA Announce the 2025 Ramin Tadayoni Award - GlobeNewswire Inc.
Stifel maintains Buy rating, $35 target on Oculis shares By Investing.com - Investing.com South Africa
Stifel maintains Buy rating, $35 target on Oculis shares - Investing.com
Oculis Holding AG Unveils Key Clinical Updates and Future Outlook at R&D Day - TipRanks
Oculis Hosts R&D Event Today to Showcase Progress on All Three Pipeline Assets - The Manila Times
Oculis completes enrolment in trials for diabetic macular oedema eye drops - Yahoo
Oculis completes enrollment for pivotal DME treatment trials By Investing.com - Investing.com South Africa
Oculis Completes Enrollment in Late-Stage Diabetic Macular Edema Trials - marketscreener.com
Oculis completes enrollment for pivotal DME treatment trials - Investing.com
Oculis Wraps Up Patient Enrollment in Late-stage Studies of Topical Eye Drug - MarketScreener
Oculis Completes Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema - The Manila Times
REG-Oculis Completes Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema - TradingView
(OCS) Trading Signals - news.stocktradersdaily.com
A First Look At Oculis Holding AG: Revenues Still Several Years Away (NASDAQ:OCS) - Seeking Alpha
Oculis to Host In-Person and Virtual R&D Day on Key Business Updates and the Development Plans for Privosegtor (OCS-05) in Acute Optic Neuritis and Beyond - The Manila Times
Oculis Holding AG (NASDAQ:OCS) Short Interest Update - Defense World
Oculis Holding AG (NASDAQ:OCS) Short Interest Down 14.1% in February - Defense World
Oculis' Insider Moves: A Glimpse into the Company's Future? - AInvest
Oculis Publishes Notifications of Transactions by Person Discharging Managerial Responsibilities - MarketScreener
Insider Buying: Oculis Holding Independent Director Bought CHF326k Of Shares - simplywall.st
Lionel Carnot Spends CHF326k On Oculis Holding Stock - Yahoo Home
Equities Analysts Set Expectations for Oculis Q1 Earnings - The AM Reporter
HC Wainwright Comments on Oculis’ Q1 Earnings (NASDAQ:OCS) - Defense World
Robert W. Baird Boosts Oculis (NASDAQ:OCS) Price Target to $41.00 - Defense World
HC Wainwright Lowers Oculis (NASDAQ:OCS) Price Target to $29.00 - Defense World
Oculis (NASDAQ:OCS) Sees Strong Trading Volume After Analyst Upgrade - Defense World
Oculis Reports Q4 and Full Year 2024 Financial Results and Provides Company Update - Informazione.it
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities - Marketscreener.com
(OCS) Investment Analysis - Stock Traders Daily
Oculis Holding AG (OCS) Reports Q4 Loss, Misses Revenue Estimates - MSN
Stifel maintains Buy on Oculis shares, price target at $35 By Investing.com - Investing.com Australia
H.C. Wainwright cuts Oculis stock target to $29, keeps Buy rating - Investing.com Australia
H.C. Wainwright cuts Oculis stock target to $29, keeps Buy rating By Investing.com - Investing.com South Africa
Oculis Holding AG Faces Heightened Cybersecurity Risks Amid Geopolitical Tensions - TipRanks
Oculis price target raised to $32 from $31 at BofA - TipRanks
Oculis (NASDAQ:OCS) Shares Gap Down Following Weak Earnings - Defense World
Oculis Holding AG Reports 2024 Financial Results - TipRanks
Oculis Reports 2024 Fourth Quarter Net Loss, Completes $100 Million Equity Financing to Support Pipeline - Vision Monday
Stifel maintains Buy on Oculis shares, price target at $35 - Investing.com
Oculis Holding AG reports results for the quarter ended December 31Earnings Summary - TradingView
Oculis Holding AG Reports 2024 Financial Results and Clinical Progress - TipRanks
Oculis (OCS) Projected to Post Quarterly Earnings on Monday - Defense World
(OCSAW) On The My Stocks Page - news.stocktradersdaily.com
Oculis Holding Ag (OCS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.15%
4.32%
자본화:
|
볼륨(24시간):